Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery

Launched by RAMBAM HEALTH CARE CAMPUS · Jan 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether giving calcium gluconate during an elective Cesarean delivery can help reduce blood loss after the surgery. Postpartum hemorrhage (PPH), which is heavy bleeding after childbirth, is a serious condition that can lead to severe complications, including the need for blood transfusions or even death. Researchers believe that calcium gluconate might help improve how the uterus contracts and reduce the risk of bleeding by supporting blood clotting.

To participate in this trial, women must be 18 years or older and scheduled for an elective Cesarean delivery at 35 weeks of pregnancy or more. However, those with certain health conditions, such as kidney problems or issues with calcium levels, cannot take part. If you join this study, you will receive calcium gluconate during your surgery, and the researchers will monitor your health to see if this treatment helps lower blood loss. Overall, this trial aims to find a safe and effective way to decrease the risks associated with heavy bleeding after childbirth.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • - Elective Cesarean Delivery, at Gestational age of 35 weeks or more.
• Exclusion Criteria:
• • Age younger than 18 years old.
• • Patients treated with calcium channel blockers.
• • Chronic renal failure and hyperphosphatemia.
• • Sarcoidosis.
• • Hypocalcemia (ionized Ca\<1 mmol/L) or hypercalcemia (ionized Ca\> 1.3 mmol/L) before the surgery.
• • Any QT abnormalities as evident by ECG before Calcium Gluconate administrations or any known conduction abnormality.